Yu Yu
Orlando, FLNPI 1245281278
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,201 of the $3,324 with a category attached, or 66.2%. 18 manufacturers reported payments, led by Janssen Research & Development, LLC at 38.5% of the total. Reporting peaked in 2019 at $1,803 and has fallen 95.5% since, to $82 in 2025.
Across 65 payments — averaging $51.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$1K
- AbbVie$364
- Kyowa Kirin, Inc.$286
- Insulet Corporation$264
- Ascendis Pharma Endocrinology Inc$168
- Biomarin Pharmaceutical Inc.$144
- plus $819 from 12 others
Across 34 payments — averaging $2801.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$61K
- Ascendis Pharma Endocrinology Inc$34K
What the payments were for
- Travel & lodging$96629%
- Food & beverage$2,20166%
- Education$1585%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 8 | $1,281 |
| AbbVie | 13 | $364 |
| Kyowa Kirin, Inc. | 4 | $286 |
| Insulet Corporation | 21 | $264 |
| Ascendis Pharma Endocrinology Inc | 1 | $168 |
| Biomarin Pharmaceutical Inc. | 2 | $144 |
| BETA Bionics, Inc. | 1 | $124 |
| Lilly USA, LLC | 1 | $123 |
| Rhythm Pharmaceuticals, Inc. | 1 | $115 |
| Ultragenyx Pharmaceutical Inc. | 1 | $104 |
| Novo Nordisk | 3 | $97 |
| Bard Peripheral Vascular, Inc. | 1 | $82 |
| Pfizer | 3 | $58 |
| Neurocrine Biosciences, Inc. | 1 | $34 |
| Tolmar Pharmaceuticals, Inc. | 1 | $23 |
| Abbott | 1 | $23 |
| Endo Pharmaceuticals Inc. | 1 | $20 |
| Sandoz | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iLet Bionic Pancreas$373
- CRYSVITA$146
- MOUNJARO$123
- ZEPBOUND$123
- Imcivree$115
- Lupron Depot$110
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.